The cGP Lab Company Profile

Background

Overview

The cGP Lab, established in 2020 and headquartered in Auckland, New Zealand, is a health and wellness company specializing in cyclic Glycine-Proline (cGP), a naturally occurring peptide. The company is dedicated to developing cGP-based products that support neurological health, metabolic balance, and healthy aging. Their flagship product, cGP-PRo®, is the world's first and only natural supplement ingredient delivering a standardized, therapeutic dose of cGP.

Mission and Vision

The cGP Lab's mission is to empower individuals to enhance their quality of life through innovative health solutions centered around cGP. Their vision is to lead in the commercialization of cGP-based products, addressing significant unmet clinical and health needs globally.

Industry Significance

Operating within the health, wellness, and fitness industry, The cGP Lab is pioneering the use of cGP to transform care for neurological conditions, metabolic health, and healthy aging. Their patented technology, backed by clinical research, positions them as a significant player in the global health and wellness market.

Key Strategic Focus

Core Objectives

The cGP Lab aims to develop and commercialize cGP-based products that support lifelong health, focusing on brain health, vascular health, and metabolic balance. Their strategic objectives include advancing cGP research, expanding product offerings, and establishing a strong market presence.

Areas of Specialization

The company specializes in the development of health supplements containing cGP, targeting brain health, circulation, and metabolic health. Their product line includes cGPMAX® Brain Health and cGPMAX® Cardiovascular Health, both containing a standardized dose of natural cGP.

Key Technologies Utilized

The cGP Lab employs proprietary manufacturing processes that combine enzymatic processing with carefully controlled blending of collagen peptides to concentrate and stabilize cGP. This innovative approach ensures the efficacy and safety of their cGP-based products.

Primary Markets Targeted

The company's primary markets include individuals over the age of 50, particularly those seeking to maintain cognitive function and vascular health as they age. Additionally, they target individuals with metabolic health concerns, such as those with type 2 diabetes, aiming to improve vascular function and overall health.

Financials and Funding

Funding History

Specific details regarding The cGP Lab's funding history, total funds raised, and recent funding rounds are not publicly disclosed. The company has received support from Callaghan Innovation, which has been instrumental in their research and development journey.

Notable Investors

Information about individual investors or venture capital firms involved with The cGP Lab is not publicly available.

Utilization of Capital

The capital raised has been utilized to advance research and development, particularly in the creation of cGP-based health supplements, and to support the commercialization of their products. The company is also focused on expanding its market presence and addressing global health challenges.

Pipeline Development

Key Pipeline Candidates

The cGP Lab's primary pipeline candidate is cGP-PRo®, a standardized cGP supplement designed to support brain health, vascular health, and metabolic balance. The company is also developing a medicated food for diabetic peripheral neuropathy, addressing a significant unmet clinical need.

Stages of Development

cGP-PRo® has been developed and is available in the market. The medicated food for diabetic peripheral neuropathy is in the development stage, with plans for clinical trials to assess its efficacy and safety.

Target Conditions

The target conditions for their products include neurological disorders, metabolic health issues, and age-related health concerns, such as cognitive decline and vascular health problems.

Anticipated Milestones

The company anticipates milestones related to the successful development and commercialization of their medicated food for diabetic peripheral neuropathy, including regulatory approvals and market launch.

Technological Platform and Innovation

Proprietary Technologies

The cGP Lab's proprietary technology involves the extraction and stabilization of cGP from New Zealand-grown blackcurrants, ensuring a standardized and therapeutic dose in their products.

Significant Scientific Methods

The company employs advanced enzymatic processing techniques combined with collagen peptide blending to concentrate and stabilize cGP, enhancing its bioavailability and effectiveness.

AI-Driven Capabilities

There is no publicly available information indicating the use of AI-driven capabilities within The cGP Lab's operations.

Leadership Team

Key Executives

Dr. Jian Guan: Chief Scientist and world-leading expert on cGP, with over 30 years of research experience and 14 international patents.

Jim Grierson: Chairman of the Board, co-founder, and blackcurrant grower.

David Eder: Co-founder and blackcurrant grower.

Nadine Morris: Operations Manager.

Victoria Watson: Marketing Manager.

Leadership Changes

In recent months, Dr. Amanda Wiggins served as CEO and played a pivotal role in shaping the company's strategy and brand. She has since moved on to pursue new opportunities, and the company is focused on building upon the progress achieved under her leadership.

Competitor Profile

Market Insights and Dynamics

The global health and wellness market is experiencing significant growth, driven by increasing consumer awareness of health issues and a focus on preventive care. The demand for natural supplements, particularly those targeting brain health and metabolic balance, is on the rise.

Competitor Analysis

While specific competitors to The cGP Lab are not detailed in the available information, the company operates in a competitive landscape with other health and wellness companies offering supplements targeting similar health concerns.

Strategic Collaborations and Partnerships

The cGP Lab has collaborated with Callaghan Innovation, a New Zealand government agency, to support their research and development efforts. This partnership has been instrumental in advancing their product development and commercialization strategies.

Operational Insights

The cGP Lab differentiates itself through its proprietary cGP extraction and stabilization technology, ensuring a standardized and therapeutic dose in their products. Their focus on natural ingredients and scientific research positions them uniquely in the health and wellness market.

Strategic Opportunities and Future Directions

The company is exploring the development of a medicated food for diabetic peripheral neuropathy, addressing a significant unmet clinical need. This initiative represents a strategic opportunity to expand their product portfolio and impact a broader consumer base.